Select Language 
English (Canada) 
English (Other Regions) 
French 
German 
Italian 
Japanese 
Russian 
Spanish 
Chinese 
VASCADE MVP®
Safe. Simple. Proven.
VASCADE MVP® venous vascular closure system provides rapid hemostasis for electrophysiology (EP) procedures, eliminating the need for manual compression and enabling patients to get up earlier. VASCADE MVP system is easy to use, and has demonstrated 0% major complications* in 1,223 patients in 5 EP clinical trials.1-5 In the AMBULATE pivotal trial,1 VASCADE MVP system has been proven to reduce time to ambulation by 64%, improve patient satisfaction by 63% and reduce opioid use post procedure by 58%. VASCADE MVP system is FDA approved for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 6-12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.6 Watch the video
VASCADE MVP® System
Make a selection to learn more
VASCADE MVP® System
0% major complications in 1,223 patients in 5 EP clinical trials1-5
Ordering Information
|
AMBULATE Trial
The AMBULATE Clinical Studies have demonstrated 0% major complications* in 1,223 total patients studied in 5 EP clinical trials, including 3 trials studying same day discharge in paroxysmal and persistent AF ablation patients.3-5
The impact of early ambulation using the VASCADE MVP® system is that every stakeholder has the potential to accomplish their specific goals and objectives. Potential goals could be same day discharge, patient satisfaction, opioid reduction, urinary catheter reduction, greater throughput, managing limited bed space and lowering overall costs.
.jpg)
Designed for EP procedures
Ordering Information
|
AMBULATE Trial
The VASCADE MVP® system is FDA approved for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 6-12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs6 and is the only extravascular closure device to offer collagen with a dual method of action, mechanical and physiological.9 Using a single operator, the VASCADE MVP system is simple and easy to use and leaves no sutures or other materials left behind in the vessel. The resorbable thrombogenic plug expands by 13X to fill the tissue tract.† The VASCADE MVP system allows for re-access, after 30 days, for repeat ablation procedures.
.jpg)
Proven by EPs
Ordering Information
|
AMBULATE Trial
VASCADE MVP® venous vascular closure system has been proven in the prospective, multicenter randomized AMBULATE Clinical Trial,1 demonstrating a 3.9 hour (64%) reduction in median time to ambulation as well a 63% improvement in patient satisfaction and a 58% reduction in opioid use post ablation, when compared to manual compression. The VASCADE MVP system has also demonstrated same day discharge success in the prospective multicenter AMBULATE Same Day Discharge Clinical Studies,4, 5 where 91.2% of patients were sent home the same day using the VASCADE MVP system.4,5 In addition, 99.7% of VASCADE MVP same day discharge patients had no intervention during follow up7 and there were zero (0%) major complications.8
.jpg)
Sharing Risks by Sharing Costs™
Ordering Information
Because Haemonetics® is so committed and confident in VASCADE MVP’s ability to safely and rapidly achieve hemostasis, we offer a unique value-based purchasing program called the VASCADE MVP® Performance Guarantee. In the event of a qualified complication as the result of VASCADE MVP, Haemonetics will provide financial reimbursement to your hospital or practice. It’s simple, we’re dedicated to exceptional outcomes for you and your patients. We stand behind our products based on proven safety and efficacy published in peer-reviewed clinical studies.
Elegantly Simple and Easy to Use
• FDA-approved for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 6-12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.6
• Dedicated to mid-bore 6-12F ID (Max 15F OD) multi-access venous closure
• Single operator
• No sutures or material left in the vessel
• Extravascular design
• No permanent or intraluminal implants
• Resorbable and thrombogenic collagen plug
• Expands to fill tissue tract
Related Training & Resources
Back to top
Webinars
Resource Center
Featured Resources View all resources
Instructions for Use
The VASCADE MVP® Venous Vascular Closure System (VVCS) is intended to seal the femoral vein access site(s) by delivering a resorbable collagen patch, extra-vascularly, at the venotomy site to aid in achieving hemostasis.
VASCADE MVP® Brochure
Our VASCADE MVP system provides rapid hemostasis for electrophysiology procedures, eliminating the need for manual compression and enabling patients to get up and moving earlier.
AMBULATE Trial
This prospective, multicenter, randomized study compared the efficacy and safety of VASCADE MVP® to manual compression for closing multiple access sites after catheter-based EP procedures.
AMBULATE Same Day Discharge Clinical Studies
This prospective, multicenter single arm registry evaluates procedural outcomes using VASCADE MVP® following atrial fibrillation interventions for patients who are discharged the same day.
Ordering Information
| Catalog Number | Description | Order Quantity |
| 700-500DX-05U | 5 French (Inner Diameter) | 1 Box (5 devices per box) |
| Catalog Number | Description | Order Quantity |
| 700-580I-05U | 6/7 French (Inner Diameter) | 1 Box (5 devices per box) |
| Catalog Number | Description | Order Quantity |
| 800-612C-10U | 6-12F Inner Diameter (15F maximum outer diameter) | 1 Box (10 devices per box) |
| Catalog Number | Description | Order Quantity |
| 800-1012XL-10U | 10-12F Inner Diameter (15F maximum outer diameter) | 1 Box (10 devices per box) |
* Major venous access site closure-related complications through the follow-up period
† Data on file at Haemonetics
1. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol 2020; 6(1):111-124.
2. Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system. VASCADE MVP following multi-access cardiac ablation procedures. J Cardiovasc Electrophysiol 2021. 32(2): 191-99.
3. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781.
4/5. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. J Cardiovasc Electrophysiol 2022. https://doi. org/10.1111/jce.15763. NCT04203329.
6. See VASCADE MVP IFU 3972 Indications for Use.
7. Venous access site closure-related complications through 15-day follow up.
8. Major venous access site closure-related complications through 15-day follow up.
9. IFUs of commercially available venous vascular closure devices: VASCADE MVP®, MYNX CONTROL™, Perclose ProGlide™ and Perclose ProStyle™. As of 9 Sep 2024.
Connect with us
